Atara Biotherapeutics

Pascal Touchon, President and CEO
San Francisco, CA
Atara is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers, and autoimmune disease. With our lead program in Phase III, Atara is the most advanced allogeneic T-cell immunotherapy company, intending to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T-cells and has the capability to treat a wide range of EBV-associated diseases, or other severe diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase III development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation CAR-T immunotherapies for both solid tumors and hematologic malignancies.

By using this website you agree to accept our Privacy Policy and Terms & Conditions